NEWARK — CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company, has received a $1 million investment from the State of Delaware to support its lead program targeting next-generation treatments for solid tumors, including head and neck and lung cancers. “We’re excited to have the State of Delaware participate in our Series A financing round as we advance toward our first-in-human clinical …